Neurocrine (NBIX) Gets a Buy from Guggenheim
Guggenheim analyst reiterated a Buy rating on Neurocrine yesterday and set a price target of $175.00.
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
In addition to Guggenheim, Neurocrine also received a Buy from J.P. Morgan’s Anupam Rama in a report issued yesterday. However, on February 12, Morgan Stanley maintained a Hold rating on Neurocrine (NASDAQ: NBIX).
Based on Neurocrine’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $805.5 million and a net profit of $153.7 million. In comparison, last year the company earned a revenue of $627.7 million and had a net profit of $103.1 million
Read More on NBIX:
Disclaimer & DisclosureReport an Issue
- Neurocrine price target lowered to $140 from $169 at Truist
- Neurocrine post-earnings selloff overdone, says JPMorgan
- Neurocrine Biosciences Earnings Call Highlights Growth Momentum
- Neurocrine price target lowered to $177 from $180 at RBC Capital
- Neurocrine price target lowered to $185 from $187 at Needham
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.